See more : Lesico Ltd (LSCO.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Caribou Biosciences, Inc. (CRBU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Caribou Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- KOSÉ Corporation (KOSCF) Income Statement Analysis – Financial Results
- Fairfax Financial Holdings Limited (FRFXF) Income Statement Analysis – Financial Results
- Canadian Natural Resources Limited (CNQ) Income Statement Analysis – Financial Results
- PT Formosa Ingredient Factory Tbk (BOBA.JK) Income Statement Analysis – Financial Results
- Aferian Plc (AFRN.L) Income Statement Analysis – Financial Results
Caribou Biosciences, Inc. (CRBU)
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 34.48M | 13.85M | 9.60M | 12.36M | 5.79M |
| Cost of Revenue | 112.08M | 3.64M | 984.00K | 34.43M | 23.64M |
| Gross Profit | -77.60M | 10.21M | 8.61M | -22.06M | -17.85M |
| Gross Profit Ratio | -225.07% | 73.71% | 89.75% | -178.50% | -308.34% |
| Research & Development | 112.08M | 82.23M | 52.26M | 34.43M | 23.64M |
| General & Administrative | 38.46M | 38.02M | 24.32M | 14.06M | 16.46M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 38.46M | 38.02M | 24.32M | 14.06M | 16.46M |
| Other Expenses | 0.00 | 7.18M | -1.35M | 514.00K | 0.00 |
| Operating Expenses | 150.54M | 120.25M | 76.58M | 48.49M | 40.09M |
| Cost & Expenses | 150.54M | 120.25M | 76.58M | 48.49M | 40.09M |
| Interest Income | 10.70M | 4.60M | 148.00K | 236.00K | 1.05M |
| Interest Expense | 0.00 | 0.00 | 8.00K | 20.00K | 4.00K |
| Depreciation & Amortization | 3.53M | 3.64M | 984.00K | 900.00K | 751.00K |
| EBITDA | -112.53M | -104.78M | -66.00M | -35.21M | -30.21M |
| EBITDA Ratio | -326.40% | -767.21% | -710.34% | -278.89% | -561.63% |
| Operating Income | -116.06M | -106.40M | -66.98M | -36.12M | -34.31M |
| Operating Income Ratio | -336.63% | -768.17% | -697.84% | -292.24% | -592.69% |
| Total Other Income/Expenses | 14.18M | 7.05M | 377.00K | -3.00K | 3.34M |
| Income Before Tax | -101.88M | -99.35M | -66.60M | -36.13M | -30.97M |
| Income Before Tax Ratio | -295.49% | -717.28% | -693.92% | -292.27% | -535.04% |
| Income Tax Expense | 193.00K | 70.00K | 321.00K | -1.82M | -7.54M |
| Net Income | -102.07M | -99.42M | -66.92M | -34.31M | -23.43M |
| Net Income Ratio | -296.05% | -717.79% | -697.26% | -277.55% | -404.82% |
| EPS | -1.38 | -1.64 | -1.11 | -0.57 | -0.39 |
| EPS Diluted | -1.38 | -1.64 | -1.11 | -0.57 | -0.39 |
| Weighted Avg Shares Out | 73.81M | 60.80M | 60.26M | 59.97M | 59.97M |
| Weighted Avg Shares Out (Dil) | 73.81M | 60.80M | 60.26M | 59.97M | 59.97M |
Caribou Biosciences Announces $25 Million Equity Investment from Pfizer
Caribou Biosciences to Participate in Upcoming Investor Conferences
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Lags Revenue Estimates
Caribou Biosciences to Participate in Upcoming Investor Conferences
Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Caribou Biosciences, Inc. (CRBU) Investors of Class Action and to Actively Participate
CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Caribou Biosciences, Inc. (NASDAQ: CRBU)
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Misses Revenue Estimates
ROSEN, A LONGSTANDING LAW FIRM, Encourages Caribou Biosciences, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – CRBU
Caribou Biosciences, Inc. (CRBU) Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Caribou Biosciences, Inc.
There's a Lot of Upside For Emerging Gene-Editing Companies
Source: https://incomestatements.info
Category: Stock Reports